(1) Whether he has been informed of the HPTN 052 study which found that effective antiretroviral (ARV) therapy for all HIV-positive individuals greatly diminishes the risk of HIV transmission; if so, what is his department's position on the study; (2) whether his department has conducted a cost and savings analysis on providing ARVs to all HIV-positive persons; if not, (a) why not and (b) when will such an analysis be conducted; if so, (i) when, (ii) who conducted the analysis and (iii) what were the findings with regard to the (aa) cost of providing ARVs to all HIV-positive persons and (bb) the projected long-term savings in terms of (aaa) reduced infection rate, (bbb) reduced opportunistic infection rate, (ccc) work force productivity and (ddd) other specified savings?